CELL INTELLIGENCE · 肿瘤细胞治疗研究

免疫细胞因子特征可预测接受溶瘤腺病毒 TILT-123 联合化疗及无 IL-2 过继性 TIL 治疗的晚期黑色素瘤患者的生存

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-fr

这些发现为 TILT-123 联合 TIL 疗法提供了机制上的见解，并为未来的生物标志物导向临床研究提出了方向。

转移性黑色素瘤中 TIL（肿瘤浸润淋巴细胞）与溶瘤腺病毒 TILT-123 联合治疗的安全性和有效性

Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.

肉瘤中的过继性 T 细胞疗法

Adoptive T-Cell Therapy in Sarcomas.

瘤内注射常规树突状细胞重振肿瘤-免疫循环治疗黑色素瘤及其他实体瘤：叙述性综述

Reinvigorating the Cancer-Immunity Cycle by Intratumoral Administration of Conventional Dendritic Cells in Melanoma and Other Solid Tumors: A Narrativ

LTX-315 与使用 TIL（肿瘤浸润淋巴细胞）过继性细胞疗法在转移性软组织肉瘤患者中产生肿瘤特异性 T 细胞

LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma

表达人 vIL-2 细胞因子的溶瘤腺病毒改善 TIL（肿瘤浸润淋巴细胞）对晚期卵巢癌的细胞毒性应答

Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a hum

转移性葡萄膜黑色素瘤的双特异性 T 细胞衔接器、细胞疗法及其他非检查点免疫疗法：叙述性综述

Bispecific T-Cell Engagers, Cell Therapies, and Other Non-Checkpoint Immunotherapies for Metastatic Uveal Melanoma: A Narrative Review.

黑色素瘤细胞与免疫疗法的进展

Advances in Cell and Immune Therapies for Melanoma.

转移性黏膜黑色素瘤患者经 TIL（肿瘤浸润淋巴细胞）与溶瘤腺病毒（TILT-123）联合治疗后获得持久完全缓解

Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastati

本病例凸显了联合免疫治疗策略作为转移性黏膜黑色素瘤患者一种有前景治疗方案的潜力。

用于基于 TIL（肿瘤浸润淋巴细胞）的过继性 T 细胞治疗的高效靶向 PD-1 的 CRISPR-Cas9

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy.